Angiotensin Receptor Blockers in Aortic Stenosis

Recruiting now · Phase 4 · Has a placebo group

Conditions studied: Aortic Stenosis, Aortic Valve Stenosis

In brief

This study is intended to investigate the effect of angiotensin receptor blockers (ARBs) on mild-to-moderate aortic stenosis.

Key facts

Study ID

NCT04913870

Run by

Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

People needed

144

Starts

2020-02-01

Expected to finish

2027-02-01

Last updated by the study team

2024-12-20

Who can join

Age: 20 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Mild to moderate aortic stenosis (peak aortic jet velocity ≥2.5 and <4m/s)
• Normal left ventricular ejection fraction (i.e. ≥50%)
• Systolic blood pressure >110 mmHg
• Diastolic blood pressure >70 mmHg

You may not qualify if…

• More than mild aortic or mitral regurgitation, or mitral stenosis
• Current use or documented indication for renin-angiotensin system medication or Aliskiren
• Known allergy or intolerance to angiotensin II receptor blockers (ARBs)
• Alzheimer, dementia or known non-compliant patient
• Renal dysfunction (glomerular filtration rate <30ml/min/1.73m2)
• Chronic hyperkalemia
• Diagnosed hepatic failure, cirrhosis, hepatitis or history of hepatic impairment
• Newly diagnosed (<2 months) or poorly controlled diabetes
• Pre-existing obstructive coronary artery disease with CCS III-IV angina or recent myocardial infarction (<3 months)
• Pregnant or lactating women
• Patients unable to read, understand or sign research consent

Where it is running

• CRIUCPQ — Québec, Quebec, Canada (enrolling)
• Odense University Hospital — Odense, Denmark (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.